{"entity":{"id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","aka":["A CD19 Targeted 4-1BB Ligand; RO7227166"],"tldr":"Englumafusp alfa is an experimental fusion protein from Hoffmann-La Roche in phase 2 trials for hodgkin lymphoma, aimed at CD19.","summary":"Englumafusp alfa (RO7227166) is a fusion protein developed by Hoffmann-La Roche. Its target is CD19 (the sponsor names CD19 x 4-1BBL). The sponsor states: Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT04077723, plans to enrol 498 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Englumafusp alfa","url":"https://clinicaltrials.gov/search?intr=RO7227166"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04077723"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"RO7227166","modality":"fusion protein","mechanism":"Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/englumafusp-alfa/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/"}]}}